INDSWFTLAB vs ONESOURCE: Stock Comparison
ONESOURCE SPECL PHARMA L is the larger company by market capitalisation. IND SWIFT LABORATORIES LT shows a higher ROE, lower leverage and a higher ROCE, while ONESOURCE SPECL PHARMA L shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
INDSWFTLAB leads 7; ONESOURCE leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | INDSWFTLAB | ONESOURCE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | INDSWFTLAB | ONESOURCE |
|---|---|---|
| Live Price | ₹345.35 | ₹1,377.8 |
| Day Change | 0.83% | 1.53% |
| Volume | 2.7 L | 1.08 L |
| 52-Week High | ₹424.75 | ₹1,925 |
| 52-Week Low | ₹87.15 | ₹1,057 |
| Distance from 52W High | -18.69% | -28.43% |
Valuation
| Metric | INDSWFTLAB | ONESOURCE |
|---|---|---|
| Market Cap | ₹3,002 Cr | ₹15,792 Cr |
| P/E Ratio | 51.3x | 0x |
| P/B Ratio | 2.17x | 2.72x |
| EPS | ₹2.84 | ₹2.18 |
| Book Value | ₹159.15 | ₹508.64 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | INDSWFTLAB | ONESOURCE |
|---|---|---|
| Revenue Growth (TTM YoY) | -66.6% | 0.5% |
| EPS Growth (TTM YoY) | -94.8% | -95.3% |
| Qtr Sales Growth | 0% | 4.86% |
| Qtr Profit Growth | 0% | 443.77% |
Profitability & Leverage
| Metric | INDSWFTLAB | ONESOURCE |
|---|---|---|
| ROE | 2.99% | 0.36% |
| ROCE | 4.37% | 1.97% |
| Net Margin | 41.4% | -5.19% |
| Operating Margin | 7.87% | 10.09% |
| Debt to Equity | 0.01x | 0.21x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | INDSWFTLAB | ONESOURCE |
|---|---|---|
| Promoter Holding | 42.93% | 30.48% |
| FII Holding | 10.78%▲ 0.08 pp | 19.19%▲ 1.69 pp |
| DII Holding | 0.2%▲ 0.03 pp | 23.38%▲ 2.77 pp |
| Public Holding | 46.09%▼ 0.11 pp | 26.94%▼ 4.47 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: IND SWIFT LABORATORIES LT and ONESOURCE SPECL PHARMA L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.